Current Affiliation Organization 【 display / non-display 】

Current Affiliation Organization 【 display / non-display 】

University 【 display / non-display 】

University 【 display / non-display 】

Graduate School 【 display / non-display 】

Graduate School 【 display / non-display 】

Study abroad experiences 【 display / non-display 】

Study abroad experiences 【 display / non-display 】

External Career 【 display / non-display 】

External Career 【 display / non-display 】

display all >>

Research Interests 【 display / non-display 】

Research Interests 【 display / non-display 】

display all >>

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

display all >>

Published Papers 【 display / non-display 】

Published Papers 【 display / non-display 】

• Renal function trajectories before and during the COVID-19 pandemic in Japanese individuals with type 1 diabetes: a post-hoc analysis of the multicenter retrospective investigation by the IPRA-CKD study group.

  Nakamura Y, Yano H, Abiru N, Nomoto H, Fukui T, Yuyama Y, Kawamura T, Ueda M, Yamamoto A, Hirota Y, Kusunoki Y, Nishida K, Sekiguchi D, Maeda Y, Minami M, Nagayama A, Iwata S, Minagawa H, Furukawa S, Miyake T, Ueno H, Chinen R, Nakayama Y, Masuzaki H, Miyachi Y, Okada Y, Okamoto M, Ono K, Tanaka KI, Kurozumi A, Sakai T, Yamasaki H, Yasui JI, Ito A, Horie I

  Endocrine journal ( 一般社団法人 日本内分泌学会 )  advpub ( 0 )   2026.09 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  <p>The coronavirus disease 2019 (COVID-19) pandemic and associated lifestyle changes have affected metabolic status in individuals with diabetes. The impact of these changes on renal function in individuals with type 1 diabetes (T1D) remains unclear. We performed a <i>post-hoc</i> analysis of a multicenter retrospective cohort study (the IPRA-CKD study) including 190 Japanese individuals with T1D who were not receiving sodium–glucose cotransporter 2 inhibitors. Participants were recruited between June 2022 and July 2023, and longitudinal data over a consecutive 60-month period preceding enrollment were extracted at 6-month intervals and divided into periods before and during the pandemic. Annual rates of estimated glomerular filtration rate (eGFR) decline were compared between the periods before and during the COVID-19 pandemic using a linear mixed-effects model. The eGFR decline was not accelerated during the pandemic compared with before the pandemic; the estimated eGFR slopes were –1.54 ± 0.28 mL/min/1.73 m²/year before the pandemic and –1.05 ± 0.22 mL/min/1.73 m²/year during the pandemic (<i>p</i> = 0.27). Glycemic control was preserved during the pandemic, despite small but significant increases in body weight, blood pressure, and insulin dose. Exploratory subgroup analyses suggested a less steep eGFR decline during the pandemic among participants with body mass index ≥25 kg/m² or those receiving renin–angiotensin system inhibitors; however, these findings should be interpreted as hypothesis-generating. In this multicenter cohort of individuals with T1D, the COVID-19 pandemic was not associated with accelerated eGFR decline overall.</p><p>Clinical Trial Registry (CTR) registration: UMIN-CTR000047441</p>

  • Access this article

    DOI
  • Search related information
    PubMed CiNii Research

• Study of weight loss intervention to find an effective strategy for obesity management and the TARGET of weight loss amount for reducing health disorders (SLIM-TARGET): a randomized controlled trial.

  Koshizaka M, Yokoh H, Ishikawa K, Hayashi A, Maeda Y, Kumagai J, Takeda K, Kaneko H, Ohno T, Ono H, Hirota Y, Sasako T, Kato T, Miyoshi K, Yamauchi T, Watanabe H, Sakaue T, Takahara M, Shimomura I, Saiki A, Tatsuno I, Takahashi K, Kurose S, Kimura Y, Onoue T, Handa T, Arima H, Eguchi J, Wada J, Miya A, Kusakabe T, Satoh-Asahara N, Irie J, Yamada-Goto N, Kondo M, Nagashima K, Sato Y, Miyazaki S, Yamamoto H, Kondo Y, Waki M, Ueno H, Nakazato M, Nakayama Y, Masuzaki H, Masaki T, Ohta M, Nishi M, Tanabe M, Iwamoto R, Senokuchi T, Horikoshi T, Tsushita K, Kadowaki T, Yokote K, SLIM-TARGET study group

  Endocrine journal ( 一般社団法人 日本内分泌学会 )  advpub ( 0 )   2026.09 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  <p>This randomized controlled study aimed to clarify weight loss targets for improving obesity-related disorders in individuals with overweight or obesity. A total of 294 participants with six obesity-related conditions were assigned to either a standard or intensive treatment group, with 12-month weight loss targets of ≥3% and ≥7%, respectively. The standard group followed the Japanese Guidelines for the Management of Obesity Disease 2016. The intensive group received frequent nutritional guidance, enhanced diet and exercise therapy, and additional pharmacotherapy. The primary outcome was weight loss and improvement in at least two obesity-related disorders at 12 months. Secondary outcomes included remission of health disorders, improvement in at least one health disorder, and visceral fat reduction. At 12 months, the weight loss was –2.5% in the intensive group and –1.7% in the standard group, with no significant difference in the primary outcome. However, remission of health disorders was achieved in 16.9% of the intensive group compared with 6.2% of the standard group (adjusted odds ratio 3.079; 95% CI 1.075–8.823; <i>p</i> = 0.036). Visceral fat reduction was greater in the intensive group (–20.46 cm² <i>vs.</i> –8.9 cm²; <i>p</i> = 0.039). Intensive treatment significantly improved blood pressure early and increased treatment motivation scores by 10.9% (95% CI: 1.2–20.6) at 24 months (<i>p</i> = 0.004). In both groups, ≥60% of the participants showed improvement in at least one disorder. Despite not achieving the target weight loss, resulting in no significant difference in the primary outcome, the intensive treatment increased remission percentages, improved early blood pressure control, and enhanced long-term treatment motivation. The study was registered at UMIN Clinical Trials Registry (UMIN ID: UMIN000031862).</p>

  • Access this article

    DOI
  • Search related information
    PubMed CiNii Research

• Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study.

  Masuzaki H, Nagashima H, Shingaki T, Oura T, Tatsuno I

  Diabetes, obesity & metabolism ( Diabetes Obesity and Metabolism )  28 ( 8 ) 6639 - 6648   2026.08 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article

    DOI
  • Search related information
    PubMed

• γ-Oryzanol, a unique ingredient specific to brown rice, effectively restores mild cognitive impairment (MCI) in obese aged mice by ameliorating microglial inflammation and promoting neurogenesis in hippocampus: Novel therapeutic insight into obesity-associated MCI

  Shiki Okamoto, Ikumi Nomura, Ayano Kinjo, Yuko Murayama, Chie Horiguchi, Chisayo Kozuka, Taiki Teruya, Tsugumi Uema, Tomoko Nagai, Michio Shimabukuro, Chitoshi Takayama, Masayuki Matsushita, Keiko Abe, Hiroaki Masuzaki

  Journal of Food Bioactives ( Tsinghua University Press )    38 - 47   2026.06 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  Abstract Obesity-diabetes syndrome poses a considerable risk for mild cognitive impairment (MCI). Our study was designed to explore therapeutic potential of γ-oryzanol (Orz), a brown rice-specific oil composed of ferulic acid ester with several phytosterols, on MCI in high-fat diet (HFD) induced obese aged mice. After being housed on an HFD for 4 months, regular Orz or the nanoparticulated form of Orz (Nano-Orz), which markedly enhances its intestinal absorption, was administered to aged mice. Mice treated with regular Orz for 4 months exhibited significant improvement in spatial cognitive function. Impressively, mice treated with Nano-Orz demonstrated cognitive improvement as early as 1 month, with substantial recovery by 3 months. In the hippocampus, treatment with both regular Orz and Nano-Orz upregulated genes associated with neurogenesis and stem cell function accompanied by a significant increase in gene expressions of anti-inflammatory cytokines. Our data highlight a therapeutic potential of Orz for obesity-associated MCI.

  • Access this article

    DOI

• Management of a Complex Orbital Post-transplantation Lymphoproliferative Disorder: A Case Report and Literature Review.

  Maruyama T, Hokama Y, Kishaba K, Kuninaka T, Kobayashi S, Nagamine H, Miyahira H, Tanaka K, Morichika K, Kawakami F, Tomita M, Wada N, Yogi A, Masuzaki H, Hamasaki T

  In vivo (Athens, Greece) ( In Vivo )  40 ( 3 ) 1824 - 1831   2026.05 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  BACKGROUND/AIM: Post-transplantation lymphoproliferative disorder (PTLD) is an uncommon but serious complication of organ transplantation. Management often requires multiple treatment modalities and reduction in immunosuppressant treatment (RIT). Orbital involvement is rare, and optimal diagnostic and therapeutic approaches remain uncertain. CASE REPORT: Here, we report a case of localized orbital PTLD that was successfully treated with RIT alone. A 62-year-old man, who had undergone kidney transplantation 18 years prior, presented with left eye pain and proptosis. Imaging revealed an enhancing intraorbital mass extending to the optic nerve and adjacent intracranial structures. Transcranial biopsy confirmed B-cell-type PTLD. The lesion regressed with stepwise RIT alone without additional therapy. The patient showed clear clinical improvement and remained in remission for more than 13 months. CONCLUSION: This case suggests the potential role of a conservative, individualized, stepwise approach in selected patients with localized orbital PTLD, and may inform management strategies for other localized forms of PTLD.

  • Access this article

    DOI
  • Search related information
    PubMed

display all >>

Books 【 display / non-display 】

Books 【 display / non-display 】

• Clinical Antiaging Medicine: Obesity, Metabolic Syndrome, and Antiaging Medicine

  Hiroaki Masuzaki ( Part: Multiple Authorship )

  springer  2025.02

• 米糠由来機能成分 γオリザノールを活用する脳機能改善・糖尿病予防のアプローチ

  益崎 裕章、小塚 智沙代、與那嶺 正人、島袋 充生 ( Part: Multiple Authorship )

  Society for Glycative Stress Research  2017

Other Papers 【 display / non-display 】

Other Papers 【 display / non-display 】

• Future prospects on 100 years healthy longevity brought by precision health and precision nutrition

  益崎裕章

  糖尿病と妊娠   25 ( 1 )   2025

   

  J-GLOBAL

• Brain science-based clinical approach for type 2 diabetes and obesity disease

  益崎裕章, 橋本龍馬, 伊敷洋平, 玉城敦子, 本間健一郎

  日本臨床   83   2025

   

  J-GLOBAL

• Eleven of specific health disturbances essential for the diagnosis of obesity disease

  益崎裕章, 玉城敦子, 伊敷洋平, 本間健一郎

  日本臨床   82 ( 10 )   2024

   

  J-GLOBAL

• Obesity and obesity disease

  益崎裕章, 玉城敦子, 伊敷洋平, 中山良朗, 本間健一郎

  日本臨床   82   2024

   

  J-GLOBAL

• Current status of hematopoietic stem cell transplantation in Okinawa

  仲地佐和子, 北村紗希子, 森近一穂, 中島知, 宮城理子, 上間道仁, 横田雄太郎, 宮城敬, 狩俣かおり, 山入端敦, 大濱昌代, 友寄未希, 友寄毅昭, 森島聡子, 福島卓也, 益崎裕章

  日本造血・免疫細胞療法学会総会プログラム・抄録集   46th   2024

   

  J-GLOBAL

display all >>

Presentations 【 display / non-display 】

Presentations 【 display / non-display 】

• 若年健康成人における腸内細菌叢（腸内フローラ）と食習慣に関する 観察研究

  上間 次己, 難波 豊隆, ジャスミン・フランシス・ミルマン, 赤嶺 ゆかり, 岡本 士毅, 益崎 裕章

  日本肥満学会  2019.11  -  2019.11 

• 沖縄 発：未来を託す子供たちに私たちが今、出来ること ～分子栄養学と脳科学からのアプローチ～

  益崎 裕章

  日本臨床内科医会  2019.10  -  2019.10 

• 合同シンポジウム１：全身加齢と局所変化

  益崎 裕章

  日本糖尿病合併症学会  2019.09  -  2019.09 

• 健康長寿社会に求められる食と行動の科学 ～沖縄の取り組みから～

  益崎 裕章, 小塚 智沙代, Jasmine F. Millman, 與那嶺 正人, 尾形 絵美, 山崎 聡, 島袋 充生, 岡本 士毅

  日本体質医学会  2019.08  -  2019.08 

Industrial Property 【 display / non-display 】

Industrial Property 【 display / non-display 】

• Metabolic Oncology

  Industrial Property No 2017-044254  (2017.04.03)

  Patent No 6015034  (2018.01.26)

Academic Awards 【 display / non-display 】

Academic Awards 【 display / non-display 】

• The Pfizer Scholars in Endocrinology Award in Recognition of Outstanding Achievement in the Advancement of Endocrinologic Science (USA)

  2013.03.15    

Grant-in-Aid for Scientific Research 【 display / non-display 】

Grant-in-Aid for Scientific Research 【 display / non-display 】

• Redefining Diagnostic Criteria for Obesity and Metabolic Syndrome through Causal Inference Applied to Large-Scale Databases

  Grant-in-Aid for Scientific Research(B)

  Project Year: 2026.04  -  2029.03 

  Direct: 6,300,000 (YEN)  Overheads: 8,190,000 (YEN)  Total: 1,890,000 (YEN)

• Grant-in-Aid for Scientific Research(C)

  Project Year: 2025.04  -  2028.03 

  Direct: 3,500,000 (YEN)  Overheads: 4,550,000 (YEN)  Total: 1,050,000 (YEN)

• Pathophysiologic molecular crosstalk in the brain between obese and alcohol-dependent states

  Grant-in-Aid for Scientific Research(C)

  Project Year: 2024.04  -  2027.03 

  Direct: 3,600,000 (YEN)  Overheads: 4,680,000 (YEN)  Total: 1,080,000 (YEN)

• Pathophysiologic molecular crosstalk in the brain between obese and alcohol-dependent states

  Grant-in-Aid for Scientific Research(C)

  Project Year: 2024.04  -  2027.03 

  Direct: 3,600,000 (YEN)  Overheads: 4,680,000 (YEN)  Total: 1,080,000 (YEN)

• Grant-in-Aid for Scientific Research(C)

  Project Year: 2023.04  -  2026.03 

  Direct: 300,000 (YEN)  Overheads: 390,000 (YEN)  Total: 90,000 (YEN)

display all >>

Social Activity 【 display / non-display 】

Social Activity 【 display / non-display 】

• 2025.09

  　

  　

  

• 2024.03

  　

  　

  

• 2023.10

  　

  　

  

• 2023.04

  　

  　

  

• 2023.03

  　

  　

  

display all >>

Media Coverage 【 display / non-display 】

Media Coverage 【 display / non-display 】

• 30分以上の座位避けて：サルコペニア肥満の懸念  Newspaper, magazine

  沖縄タイムス  2023.2

  Author： Myself 

• 世界糖尿病デー：定期健診で早期発見重要  Newspaper, magazine

  沖縄タイムス  2022.11

  Author： Myself 

• 『長寿県沖縄』今は昔：沖縄復帰50周年  Internet

  時事通信デジタル  2022.5

  Author： Myself 

• 糖尿病薬で血液がん抑制  Newspaper, magazine

  琉球新報  2022.4

  Author： Myself 

• 今こそ栄養学のすすめ  Newspaper, magazine

  読売新聞  2021.1

  Author： Myself 

display all >>

Academic Activities 【 display / non-display 】

Academic Activities 【 display / non-display 】

• （ ホテル ザ・ナハテラス（沖縄県　那覇市） ）

  2024.8

  　

  　

  種別： Academic society, research group, etc. 

  　View Summary

  金井好克先生 大阪大学 ヒューマン・メタバース疾患研究拠点 疾患代謝シグナル制御学　特任教授 特別講演：SGLT２阻害薬がもたらす２型糖尿病治療の新たな視点～創薬から振り返る～

• （ 沖縄ハーバービューホテル（沖縄県　那覇市） ）

  2024.8

  　

  　

  種別： Academic society, research group, etc. 

  　View Summary

  山田裕揮先生 株式会社Medii 代表取締役 医師 基調講演：医師の調べ物改革：Chat GPTの上手な活用法

• （ ホテル ザ・ナハテラス（沖縄県　那覇市） ）

  2024.7

  　

  　

  種別： Academic society, research group, etc. 

  　View Summary

  古川慎哉先生 愛媛大学 総合健康センター 教授 特別講演：睡眠障害と糖尿病：夜間頻尿を中心に

• 2024.6

  　

  　

  種別： Academic society, research group, etc. 

  　View Summary

  寺内康夫先生　横浜市立大学大学院医学研究科 分子内分泌・糖尿病内科学 教授 特別講演：インクレチン製剤導入のポイント：DPP-4阻害薬と経口GLP-1受容体作動薬の使い分けを含めて

• （ 沖縄県立博物館・美術館（沖縄県　那覇市） ）

  2024.6

  　

  　

  種別： Academic society, research group, etc. 

  　View Summary

  桑原宏一郎先生　信州大学医学部循環器内科学教室 教授 特別講演：糖尿病合併高血圧患者の治療戦略：EAGLE-DH試験を含めて

display all >>